Infusio Mannitoli

Mannitol, the active ingredient in Infusio Mannitoli, is an osmotic diuretic presented as a sterile solution for injection for intravenous use. It is employed in hospital settings to lower intracranial and intraocular pressure and to promote diuresis in acute renal failure.

GNH USA supplies Infusio Mannitoli as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company follows EU GMP standards and provides reliable logistics for global procurement.

Mannitol is used as an osmotic agent to manage conditions where fluid shifts reduce pressure or support renal clearance.

- Increased intracranial pressure: reduces cerebral edema and lowers intracranial pressure. - Acute renal failure: enhances osmotic diuresis to aid removal of excess fluid and waste products. - Glaucoma: decreases intraocular pressure by drawing fluid from the eye.

Mannitol may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Headache - Nausea - Vomiting - Thirst - Dizziness - Electrolyte imbalance (e.g., hyponatremia, hypokalemia)

Serious or Rare Side Effects: - Pulmonary edema - Severe hypotension - Anaphylactic reaction - Cardiac arrhythmia - Acute renal failure worsening - Metabolic acidosis

When using mannitol, clinicians should observe specific precautions to minimize risks.

- Renal function: assess baseline renal status and avoid use in anuric patients. - Electrolyte balance: monitor serum sodium, potassium and osmolality during therapy. - Cardiovascular status: watch for hypotension, especially in hypovolemic patients. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - Drug interactions: review concomitant medications that may potentiate fluid shifts or electrolyte disturbances. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mannitol can interact with several drugs, affecting fluid balance or cardiovascular stability.

Major Interactions (Avoid): - Loop diuretics: may cause excessive fluid loss and electrolyte depletion. - Insulin: can enhance hypoglycemic effect when combined with mannitol‑induced fluid shifts. - Lithium: mannitol may increase lithium serum concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: additive hypotensive effect may require blood pressure monitoring. - NSAIDs: may blunt diuretic response and affect renal perfusion. - Other antihypertensives: combined use can lead to marked blood pressure reductions.